Donanemab Approved in the U.S.
The antibody becomes the second amyloid immunotherapy to receive traditional FDA approval, joining Leqembi.
6 RESULTS
Sort By:
The antibody becomes the second amyloid immunotherapy to receive traditional FDA approval, joining Leqembi.
New candidate OXD-2314 binds 3R and 4R forms of tau and has begun Phase 1. The pan-tau tracer APN-1607 begins Phase 3 for progressive supranuclear palsy, a 4R tauopathy.
To modulate synapses, Aη weakens ion flux through glutamate receptors and strengthens their non-ionotropic signaling. This dual action is a first, say scientists.
In mouse models of amyloidosis, CD8+ T cells trigger myelin pathology by rousing microglia and confusing oligodendrocytes.
Mice missing microglia develop astrogliosis and neurodegeneration by middle age. Giving them healthy microglia prevents or reverses pathology.
Nixing an endosomal targeting sequence shields APP from BACE1, reducing Aβ and pathologic C-terminal fragments in mice.